Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arcus And Gilead Keep TIGIT Dream Alive Despite Trial Shortcomings

Still In The Game After Mixed Phase II Results

Executive Summary

Arcus and Gilead’s latest Phase II readout has produced mixed signals, but some analysts are reassured about the potential of domvanalimab and the wider TIGIT field.

You may also be interested in...

Gilead Increases Investment In Arcus; Firms Abandon Chemo-Free Combo Study

With a $320m equity investment, Gilead will now own 33% of partner Arcus, which it said reinforces its optimism around the anti-TIGIT class for oncology.

As Gilead’s PD-1/TIGIT Trial Falls Short, Oncologists Say Better Biomarkers Needed

The ARC-7 trial showed a progression-free survival benefit in NSCLC, but the PFS benefit for zimberelimab/domvanalimab wasn’t as big as analysts and oncologists had hoped.

Gilead Adds Inflammation Targets To Its 2020 R&D Collaboration With Arcus

Deal Snapshot: Already partnered on an anti-TIGIT drug and other immuno-oncology candidates, the firms will team up further on four targets in inflammatory disease.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts